Steve Fermi
Plus aucun poste en cours
Profil
Steve Fermi held several positions in clinical affairs and studies, including Director of Clinical Affairs at Cygnus, Inc. and Director of Clinical Studies at Keravision, Inc. He also served as Executive Director of Clinical Affairs at Asthmatx, Inc. and Broncus Technologies, Inc., and as Vice President of Clinical Affairs at PneumRx LLC and BaroSense, Inc. Fermi received his undergraduate degree from Ball State University and his graduate degree from San Francisco State University.
He also holds an MBA from the University of California, Berkeley.
Anciens postes connus de Steve Fermi
| Sociétés | Poste | Fin |
|---|---|---|
Asthmatx, Inc.
 Asthmatx, Inc. Medical SpecialtiesHealth Technology Asthmatx, Inc. develops catheter-based outpatient procedure that provides asthma control for adult severe asthma patients. The company was founded in 2003 and is headquartered in Sunnyvale, CA. | Directeur Technique/Scientifique/R&D | 01/07/2007 |
PneumRx LLC
 PneumRx LLC Medical SpecialtiesHealth Technology PneumRx, Inc. operates as a medical device company which focuses on developing minimally-invasive solutions for unmet medical needs in pulmonary medicine. Its product is a minimally invasive device intended to improve exercise capacity, lung function, and quality of life in patients with both heterogeneous and homogeneous emphysema. The company was founded by by Erin McGurk, Mark L. Mathis, and Ronald Dieck in 2004 and is headquartered in Mountain View, CA. | Directeur Technique/Scientifique/R&D | - |
| Nellcor, Inc. | Corporate Officer/Principal | - |
Keravision, Inc.
 Keravision, Inc. Medical SpecialtiesHealth Technology Keravision, Inc. was developed medical products for the treatment of common vision problems. The company was developed a new category of non-laser vision correction products for the treatment of common vision disorders, including myopia, hyperopia and astigmatism, to offer an alternative to eyeglasses, contact lenses and other vision correction surgical procedures. Its first product, Intacs corneal ring segments, based on its proprietary patented technology, has been approved by the FDA for correcting mild myopia. Intacs are the first surgical vision correction technology to be approved by the FDA for distribution and sales that is designed to permanently correct a patient's vision while providing the option of removability. Intacs are composed of two thin half-circles of polymer material that are inserted into the periphery of the cornea to reshape the curvature of the cornea to correct vision. | Corporate Officer/Principal | - |
Cygnus, Inc.
 Cygnus, Inc. Medical SpecialtiesHealth Technology Cygnus, Inc. develops and manufactures glucose-monitoring devices. The company develops devices that provide data to individuals and physicians to enable them to manage diabetes. It was founded in 1985 and is headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Steve Fermi
| Ball State University (Indiana) | Undergraduate Degree |
| San Francisco State University | Graduate Degree |
| University of California, Berkeley | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 7 |
|---|---|
BaroSense, Inc.
 BaroSense, Inc. Medical SpecialtiesHealth Technology BaroSense Inc. operates as a medical device company that focuses on the research and development of minimally invasive medical devices for the treatment of obesity. The company was founded by Richard S. Stack and William N. Starling, Jr. in 2001 and is headquartered in Redwood City, CA. | Health Technology |
Broncus Technologies, Inc.
 Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | Health Technology |
Asthmatx, Inc.
Asthmatx, Inc. Medical SpecialtiesHealth Technology Asthmatx, Inc. develops catheter-based outpatient procedure that provides asthma control for adult severe asthma patients. The company was founded in 2003 and is headquartered in Sunnyvale, CA. | Health Technology |
Cygnus, Inc.
Cygnus, Inc. Medical SpecialtiesHealth Technology Cygnus, Inc. develops and manufactures glucose-monitoring devices. The company develops devices that provide data to individuals and physicians to enable them to manage diabetes. It was founded in 1985 and is headquartered in San Francisco, CA. | Health Technology |
Keravision, Inc.
Keravision, Inc. Medical SpecialtiesHealth Technology Keravision, Inc. was developed medical products for the treatment of common vision problems. The company was developed a new category of non-laser vision correction products for the treatment of common vision disorders, including myopia, hyperopia and astigmatism, to offer an alternative to eyeglasses, contact lenses and other vision correction surgical procedures. Its first product, Intacs corneal ring segments, based on its proprietary patented technology, has been approved by the FDA for correcting mild myopia. Intacs are the first surgical vision correction technology to be approved by the FDA for distribution and sales that is designed to permanently correct a patient's vision while providing the option of removability. Intacs are composed of two thin half-circles of polymer material that are inserted into the periphery of the cornea to reshape the curvature of the cornea to correct vision. | Health Technology |
| Nellcor, Inc. | Health Technology |
PneumRx LLC
PneumRx LLC Medical SpecialtiesHealth Technology PneumRx, Inc. operates as a medical device company which focuses on developing minimally-invasive solutions for unmet medical needs in pulmonary medicine. Its product is a minimally invasive device intended to improve exercise capacity, lung function, and quality of life in patients with both heterogeneous and homogeneous emphysema. The company was founded by by Erin McGurk, Mark L. Mathis, and Ronald Dieck in 2004 and is headquartered in Mountain View, CA. | Health Technology |